I‑BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro

Fan,Jianping; Zhao,Jian; Shao,Jie; Wei,Xianzhao; Zhu,Xiaodong; Li,Ming

doi:10.3892/etm.2017.5032

I‑BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro

Authors:
- Jianping Fan
- Jian Zhao
- Jie Shao
- Xianzhao Wei
- Xiaodong Zhu
- Ming Li
View Affiliations

Affiliations: Department of Orthopedics, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: August 25, 2017 https://doi.org/10.3892/etm.2017.5032
Pages: 4602-4606

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ankylosing spondylitis (AS) is characterized by osteoclastogenesis and inflammatory bone resorption. The present study aimed to investigate the effect of bromodomain and extra‑terminal domain (BET) protein inhibitor I‑BET151 on AS process. A total of 38 AS Chinese patients were recruited and a further 38 sex‑ and age‑matched healthy participants were selected as control. The Bath AS Function Index and Bath AS Disease Activity Index were assessed in AS patients and levels of erythrocyte sedimentation rate and C‑reactive protein were measured in AS and healthy groups. Serum from AS patients was used to induce MG63 osteoblasts and BET inhibitor I‑BET151 at concentrations of 50, 100 and 200 ng/ml used for treatment of the cells. A HLA‑B27/β2m transgenic AS Lewis rat model was established and treated with 30 mg/kg I‑BET151 for 5 weeks. Levels of receptor activator of nuclear factor‑κB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and MMP9 were measured using ELISA in vivo and additionally detected with western blotting and polymerase chain reaction in vitro. The levels of RANKL, OPG, MMP3 and MMP9 were upregulated in AS serum, AS serum treated MG63 cells and HLA‑B27/β2m transgenic AS rats. Conversely, levels of RANKL, OPG, MMP3 and MMP9 were significantly inhibited in cells or animals treated with I‑BET151. Overall, the results of the present study demonstrated that BET inhibitor I‑BET151 suppresses levels of RANKL, OPG, MMP3 and MMP9 in AS in vivo and in vitro. I‑BET151 may exhibit the potential to be used as a therapeutic in the treatment of AS patients.

View Figures

View References

1	Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, Resch H and Pietschmann P: Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int. 28:987–993. 2008. View Article : Google Scholar : PubMed/NCBI
2	Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, Taylor GJ and Bhalla AK: Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther. 14:R1272012. View Article : Google Scholar : PubMed/NCBI
3	Siebuhr AS, Wang J, Karsdal M and Bay-Jensen ACYJQZ: Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis. J Transl Med. 10:1952012. View Article : Google Scholar : PubMed/NCBI
4	Hu Z, Lin D, Qi J, Qiu M, Lv Q, Li Q, Lin Z, Liao Z, Pan Y, Jin O, et al: Serum from patients with ankylosing spondylitis can increase PPARD, fra-1, MMP7, OPG and RANKL expression in MG63 cells. Clinics (Sao Paulo). 70:738–742. 2015. View Article : Google Scholar : PubMed/NCBI
5	Raju R, Balakrishnan L, Nanjappa V, Bhattacharjee M, Getnet D, Muthusamy B, Thomas Kurian J, Sharma J, Rahiman BA, Harsha HC, et al: A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway. Database (Oxford). 2011:bar0212011. View Article : Google Scholar : PubMed/NCBI
6	Mou YK, Zhang PP, Li QX, Lin ZM, Liao ZT, Wei QJ and Gu JR: Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes. Clin Rheumatol. 34:1085–1089. 2015. View Article : Google Scholar : PubMed/NCBI
7	Barrett E, Brothers S, Wahlestedt C and Beurel E: I-BET151 selectively regulates IL-6 production. Biochim Biophys Acta. 1842:1549–1555. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lamoureux F, Baud'huin M, Calleja Rodriguez L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE, Heymann D and Ory B: Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat Commun. 5:35112014. View Article : Google Scholar : PubMed/NCBI
9	Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, et al: Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 123:697–705. 2014. View Article : Google Scholar : PubMed/NCBI
10	Parkmin KH, Lim E, Lee MJ, Park SH, Giannopoulou E, Yarilina A, van der Meulen M, Zhao B, Smithers N, Witherington J, et al: Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nat Commun. 5:54182013. View Article : Google Scholar
11	Zochling J and Braun J: Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 21:699–712. 2007. View Article : Google Scholar : PubMed/NCBI
12	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P and Jenkinson T: A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 21:2281–2285. 1994.PubMed/NCBI
13	Li X, He L, Hu Y, Duan H, Li X, Tan S, Zou M, Gu C, Zeng X, Yu L, et al: Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways. PLoS One. 8:e742742013. View Article : Google Scholar : PubMed/NCBI
14	He L, Duan H and Li X, Wang S, Zhang Y, Lei L, Xu J, Liu S and Li X: Sinomenine down-regulates TLR4/TRAF6 expression and attenuates lipopolysaccharide-induced osteoclastogenesis and osteolysis. Eur J Pharmacol. 779:66–79. 2016. View Article : Google Scholar : PubMed/NCBI
15	Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, Davin S, Pan Y, Cambronne ED, Dorris M, et al: HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLoS One. 9:e1056842014. View Article : Google Scholar : PubMed/NCBI
16	Rysnik O, McHugh K, van Duivenvoorde L, van Tok M, Taurog J, Kollnberger S, Baeten D and Bowness P: Data showing non-conventional HLA-B27 expression in axial joints and gut tissue from B27 transgenic rats, and in frozen and paraffin-fixed synovial SpA tissue. Data Brief. 9:100–111. 2016. View Article : Google Scholar : PubMed/NCBI
17	Atkinson SM, Bleil J, Maier R, Kühl AA, Thorn M, Serikawa K, Fox B, Kruse K, Haase C, Skov S, et al: Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model. Arthritis Res Ther. 18:282016. View Article : Google Scholar : PubMed/NCBI
18	Reveille JD: Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 34:1009–1018. 2015. View Article : Google Scholar : PubMed/NCBI
19	Baud'huin M, Lamoureux F, Jacques C, Calleja Rodriguez L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, et al: Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Bone. 94:10–21. 2017. View Article : Google Scholar : PubMed/NCBI
20	Shaw AT and Gravallese EM: Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol. 49:2–10. 2015. View Article : Google Scholar : PubMed/NCBI
21	Im CH, Kang EH, Ki JY, Shin DW, Choi HJ, Chang EJ, Lee EY, Lee YJ, Lee EB, Kim HH and Song YW: Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. Clin Exp Rheumatol. 27:620–625. 2009.PubMed/NCBI